source
- AbbVie halts development of livmoniplimab after deeming benefit limitedAbbVie announced it is discontinuing the phase 2 development of its monoclonal antibody livmoniplimab (ABBV-151) after concluding the drug is unlikely to outperform existing therapies. The drug wa…
- Stakeholders submit over 500 comments urging FDA to shape regulation of generative AI medical devicesOver 500 comments have been filed in response to the FDA's discussion paper on generative AI-enabled medical devices. The feedback reflects a wide range of viewpoints. Some participants recommend…